Sök i LIBRIS databas

  Utökad sökning


Sökning: onr:"swepub:oai:DiVA.org:kth-227355" > Combined ASRGL1 and...

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma

Huvila, J. (författare)
Laajala, T. D. (författare)
Edqvist, P. -H (författare)
visa fler...
Mardinoglu, Adil, (författare)
KTH, Science for Life Laboratory, SciLifeLab, Department of Biology and Biological Engineering, Chalmers University of Technology, 41296 Gothenburg, Sweden
Talve, L. (författare)
Pontén, F. (författare)
Grénman, S. (författare)
Carpén, O. (författare)
Aittokallio, T. (författare)
Auranen, A. (författare)
Grenman, Seija, (författare)
Univ Turku, Turku Univ Hosp, Dept Gynaecol & Obstet, Pl52, FIN-20520 Turku, Finland
Carpen, Olli, (författare)
Univ Turku, Turku Univ Hosp, Dept Pathol, Pl 52, FIN-20520 Turku, Finland;Univ Helsinki, Dept Pathol, Helsinki, Finland;Finland HUSIAB, Pl720, Helsinki 00029, Finland
Ponten, F., (författare)
Uppsala universitet, Uppsala University
visa färre...
KTH Centra. Science for Life Laboratory, SciLifeLab. (creator_code:org_t)
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet. Medicinska fakulteten. Institutionen för immunologi, genetik och patologi. Experimentell och klinisk onkologi. (creator_code:org_t)
visa fler...
Uppsala universitet Science for Life Laboratory, SciLifeLab. (creator_code:org_t)
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet. Medicinska fakulteten. Institutionen för immunologi, genetik och patologi. Klinisk och experimentell patologi. (creator_code:org_t)
visa färre...
Ingår i: Gynecologic Oncology. - Academic Press Inc.. - 0090-8258. ; 149:1, s. 173-180
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
  • Objective: In clinical practise, prognostication of endometrial cancer is based on clinicopathological risk factors. The use of immunohistochemistry-based markers as prognostic tools is generally not recommended and a systematic analysis of their utility as a panel is lacking. We evaluated whether an immunohistochemical marker panel could reliably assess endometrioid endometrial cancer (EEC) outcome independent of clinicopathological information. Methods: A cohort of 306 EEC specimens was profiled using tissue microarray (TMA). Cost- and time-efficient immunohistochemical analysis of well-established tissue biomarkers (ER, PR, HER2, Ki-67, MLH1 and p53) and two new biomarkers (L1CAM and ASRGL1) was carried out. Statistical modelling with embedded variable selection was applied on the staining results to identify minimal prognostic panels with maximal prognostic accuracy without compromising generalizability. Results: A panel including p53 and ASRGL1 immunohistochemistry was identified as the most accurate predictor of relapse-free and disease-specific survival. Within this panel, patients were allocated into high- (5.9%), intermediate- (29.5%) and low- (64.6%) risk groups where high-risk patients had a 30-fold risk (P < 0.001) of dying of EEC compared to the low-risk group. Conclusions: P53 and ASRGL1 immunoprofiling stratifies EEC patients into three risk groups with significantly different outcomes. This simple and easily applicable panel could provide a useful tool in EEC risk stratification and guiding the allocation of treatment modalities. 


MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Obstetrics, Gynecology and Reproductive Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)


Endometrial cancer
Risk stratification
antineoplastic agent
asrg1 protein
epidermal growth factor receptor 2
estrogen receptor
Ki 67 antigen
l1cam protein
MutL protein homolog 1
progesterone receptor
protein p53
tumor marker
unclassified drug
cancer chemotherapy
cancer grading
cancer recurrence
cancer surgery
cancer survival
disease specific survival
endometrium carcinoma
follow up
high risk patient
human tissue
low risk patient
major clinical study
middle aged
overall survival
priority journal
recurrence free survival
recurrent disease
tissue microarray

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy